


Factsheet: Zelda Therapeutics Ltd

Zelda Therapeutics Ltd ("Zelda") is a biotechnology company focused on developing medical cannabis therapies from an exclusive set of patient data providing strong evidence of therapeutic successes. It has forged a number of international collaborations with key opinion leaders and has pre-clinical programs underway in breast and brain cancer and is planning on commencing clinical trials in 2017 in the areas of insomnia and certain dermatological indications. It listed on the ASX in November 2016 following a \$4 million capital raising.

Capital Structure



Zelda Therapeutics Ltd	ASX: ZLD
Total Shares on Issue	670m*
Escrowed shares on issue (~50%)	347m
Options	40m
Market Capitalisation @ \$3.5c	\$23m
Cash at bank (as at listing on 22 Nov 16)	\$4m

What We Do

Through an exclusive license to Aunt Zelda's patient data set of over 500 patients gathered over several years Zelda designs clinical trials using established formulations and protocols.

- Aunt Zelda's is a pioneering Californian company founded in the medical cannabis field
- Clinical trials to initially focus on sleep disorders and dermatology indications with additional pre-clinical research in cancer
- Zelda partners with leading research institutions to progress research and trials to generate IP
- Will generate income through licensing and distribution deals with third parties

Business and Revenue Model



Revenue streams



Leading Board and Management Team

Harry Karelis - Founder & Executive Chairman

Harry is the founder of Titan Capital Partners and has in excess of 24 years of diversified experience in the financial services sector including specialist med-tech private equity investing.



Mara Gordon - Founder & Director

Mara is the co-founder of Aunt Zelda's and Zelda Therapeutics. She specialises in the development of cannabis extract treatment protocols for seriously ill patients in California.



Jason Peterson - Founder & Director

Jason is a Director, major shareholder and Head of Corporate at boutique stock broking and investment banking firm, CPS Capital. He has more than 21 years of experience in the financial advisory sector



Dr Stewart Washer - Founder & Director

Stewart has 20 years of CEO and Board experience in medical technology, biotech and agrifood companies. He is currently Chairman of ASX-listed Orthocell Ltd, Cynata Therapeutics Ltd and Chairman of privately-held Minomic International Ltd.



How Medical Cannabis Works

Cannabis contains more than 85 types of cannabinoids, the chemical compounds secreted by cannabis flowers

Cannabinoids bind to receptor sites in the brain and body, mimicking naturally occurring endocannabinoids

CB1 and CB2 are cannabinoid receptors founds in the brain, central nervous system and some peripheral organs and tissues

Different medical effects can be achieved by targeting different receptors, using different types or quantities of cannabinoids

Strong Partnerships In Place With World Leaders In Medical Cannabis



Exclusive patient data access agreement in place with Aunt Zelda's includes formulations & protocols

Manufacturing agreement in place with AusCann, an Australian company working with Canopy Growth/Tweed, Canada's largest medical cannabis company, to supply clinical trial material

One of the largest, medical research institutes in Australia, comprising more than 500 staff and students for pre-clinical testing in the area of children's brain cancers

Collaboration with Curtin University to undertake pre-clinical research on pancreatic cancer

Partnership in place with the prestigious Complutense University Madrid for pre-clinical research in cancer

Exclusive access to CDRMed for clinical trial use, software that creates the best formulations of medicinal cannabis based on the Aunt Zelda's database

Significant Patient Markets

Breast Cancer

- Over 1.5 million patients in 2010
- Expected to exceed \$13 billion by 2020

Source: GBI Research

Eczema

- Over 334 million dermatitis sufferers globally
- Estimated to be worth 7.3 billion globally by 2024

Source: Global data 2015, Wikipedia

Insomnia

- Affects approximately 35% of the global population

Source: GlobalData, Feb 2015

Glioblastoma

Rare disease represents over 15% of all primary brain tumours

Source: American Brain Tumor Association

Pancreatic Cancer

- 12th most common cancer in men and women around the world
- Estimated that 418,00 new cases will be diagnosed by 2020

Source: World Pancreatic Cancer Day

Investment Proposition

Global opportunity is opening up for medical cannabis



Focus on large patient populations, with low cost, short duration trials



Leading industry board and management expertise



Strong partnerships with global leaders in the medical cannabis market



Active news flow pipeline with multiple near term share price catalysts



Clear strategy and revenue model to generate significant upfront and recurring fees



Contact:

E: enquiries@zeldatherapeutics.com